| Attributes | Values |
|---|
| rdf:type
| |
| Description
| - The chapter resumes all findings obtained up to now in our laboratories in the study of effect of cyclin-dependent kinases inhibitors (CDKI) on cancer cells. In the beginning, the history of discovery of inhibitory effects of trisubstituted purins on cell divisions is introduced. Furthermore, proteomic studies on cancer cells resistant and sensitive to these anti-cancer drugs are described. Results of analyses on transcriptomic level and proteomic level are compared suggesting low correlations between the mRNA and the encoded protein levels. In T-lymphoblastic leukaemia cell line CEM sensitive to CDKI a decrease in level of signalling adaptor Crk-like protein was observed after CDKI treatment. This depression of total level of Crk-like protein and also of its phosphorylation at Tyr207 was confirmed by westernblotting. Additional immunohistochemical staining of mouse tumor confirmed in vivo the effect of CDKI on Crk-like levels. These findings proved the importance of proteomic studies in candida...
- The chapter resumes all findings obtained up to now in our laboratories in the study of effect of cyclin-dependent kinases inhibitors (CDKI) on cancer cells. In the beginning, the history of discovery of inhibitory effects of trisubstituted purins on cell divisions is introduced. Furthermore, proteomic studies on cancer cells resistant and sensitive to these anti-cancer drugs are described. Results of analyses on transcriptomic level and proteomic level are compared suggesting low correlations between the mRNA and the encoded protein levels. In T-lymphoblastic leukaemia cell line CEM sensitive to CDKI a decrease in level of signalling adaptor Crk-like protein was observed after CDKI treatment. This depression of total level of Crk-like protein and also of its phosphorylation at Tyr207 was confirmed by westernblotting. Additional immunohistochemical staining of mouse tumor confirmed in vivo the effect of CDKI on Crk-like levels. These findings proved the importance of proteomic studies in candida... (en)
- V kapitole jsou shrnuty dosavadní poznatky získané v našich laboratořích studiem účinku inhibitorů cyklin-dependentních kináz na nádorové buňky. V úvodu je představena historie objevení inhibičních účinků trisubstituovaných purinů na dělení buněk. Dále jsou popsány studie proteomů nádorových buněk vnímavých a rezistentních k těmto protinádorovým lékům. Jsou zde porovnány výsledky transkriptomových a proteomových studií, ze kterých vyplývá nízká korelace mezi hladinou mRNA a hladinou proteinu kódovaného touto mRNA. U buněk T-lymfoblastické leukémie linie CEM, která je vnímavá k působení inhibitorů, bylo po působení inhibitoru CDK pozorováno snížení hladiny signálního adaptorového proteinu Crk-like. Pomocí imunoblotu se specifickými protilátkami bylo povrzeno snížení hladiny celkového Crk-like proteinu i snížení jeho fosforylace na tyrozinu 207 po působení CDK inhibitoru. Pokles Crk-like i jeho fosforylace byl prokázán i in vivo imunohistochemickým barvením myšího nádoru léčeného CDK inhibitorem. ... (cs)
|
| Title
| - Cyclin-dependent kinase inhibitors and cancer: usefulness of proteomic approaches in assessment of the molecular mechanisms and efficacy of novel therapeutics
- Inhibitory cyklin-dependentních kináz a rakovina: využití proteomových studií k určení molekulárních mechanismů a účinnosti nových léčiv (cs)
- Cyclin-dependent kinase inhibitors and cancer: usefulness of proteomic approaches in assessment of the molecular mechanisms and efficacy of novel therapeutics (en)
|
| skos:prefLabel
| - Cyclin-dependent kinase inhibitors and cancer: usefulness of proteomic approaches in assessment of the molecular mechanisms and efficacy of novel therapeutics
- Inhibitory cyklin-dependentních kináz a rakovina: využití proteomových studií k určení molekulárních mechanismů a účinnosti nových léčiv (cs)
- Cyclin-dependent kinase inhibitors and cancer: usefulness of proteomic approaches in assessment of the molecular mechanisms and efficacy of novel therapeutics (en)
|
| skos:notation
| - RIV/61388971:_____/07:00094564!RIV08-AV0-61388971
|
| http://linked.open.../vavai/riv/strany
| |
| http://linked.open...avai/riv/aktivita
| |
| http://linked.open...avai/riv/aktivity
| - Z(AV0Z50200510), Z(AV0Z50450515)
|
| http://linked.open...vai/riv/dodaniDat
| |
| http://linked.open...aciTvurceVysledku
| |
| http://linked.open.../riv/druhVysledku
| |
| http://linked.open...iv/duvernostUdaju
| |
| http://linked.open...titaPredkladatele
| |
| http://linked.open...dnocenehoVysledku
| |
| http://linked.open...ai/riv/idVysledku
| - RIV/61388971:_____/07:00094564
|
| http://linked.open...riv/jazykVysledku
| |
| http://linked.open.../riv/klicovaSlova
| |
| http://linked.open.../riv/klicoveSlovo
| |
| http://linked.open...ontrolniKodProRIV
| |
| http://linked.open...i/riv/mistoVydani
| |
| http://linked.open...i/riv/nazevZdroje
| - Clinical Proteomics. From Diagnosis to Therapy
|
| http://linked.open...in/vavai/riv/obor
| |
| http://linked.open...ichTvurcuVysledku
| |
| http://linked.open...cetTvurcuVysledku
| |
| http://linked.open...UplatneniVysledku
| |
| http://linked.open...iv/tvurceVysledku
| - Halada, Petr
- Gadher, S. J.
- Kovářová, Hana
- Skalníková, Helena
- Džubák, P.
- Hajdúch, M.
- Strnad, M.
- Vydra, D.
- Dziechciarková, M.
- Radioch, D.
|
| http://linked.open...n/vavai/riv/zamer
| |
| number of pages
| |
| http://purl.org/ne...btex#hasPublisher
| |
| https://schema.org/isbn
| |
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)